Goldman Sachs Group Inc Tg Therapeutics, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TGTX
# of Institutions
340Shares Held
88.5MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$539 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$399 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$318 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$125 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$112 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.08B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...